Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

By E. Olsen, M. Duvic, A. Frankel, Youn H. Kim, Ann G. Martin, E. Vonderheid, B. Jegasothy, G. Wood, M. Gordon, Peter D. Heald and 16 more. Journal of Clinical Oncology, 2001

615 citations recorded by the source corpus.

Subfields: Dermatology, Immunology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/97a2659b9a697061cf1a9756e1fd34486bfb1537

Citations in the corpus

• Romidepsin in the treatment of cutaneous T-cell lymphoma (2011, neutral): “Pruritus was reported monthly by the patients using a 100 mm visual analog scale (VAS).(37,38) These various scores and scales were felt to be a better marker of overall meaningful tumor response.”